Pulmatrix (NASDAQ:PULM) Announces Earnings Results

Pulmatrix (NASDAQ:PULM) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $1.71, FiscalAI reports.

Pulmatrix Trading Up 1.3%

PULM stock traded up $0.02 during mid-day trading on Friday, reaching $1.53. 17,769 shares of the stock traded hands, compared to its average volume of 10,608. Pulmatrix has a 52-week low of $1.16 and a 52-week high of $5.50. The stock’s fifty day moving average is $1.62 and its 200-day moving average is $1.76. The company has a market cap of $5.58 million, a P/E ratio of -1.39 and a beta of 1.91.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix as of its most recent filing with the Securities and Exchange Commission. 11.84% of the stock is owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).